ViaCyte Company
ViaCyte is a preclinical therapeutic company specializing in regenerative medicine therapies for diabetes. Their therapy is based on the differentiation of stem cells into pancreatic beta-cell precursors, with subcutaneous implantation in an encapsulation device.
Investors
%20.jpg)
.png)
%20.jpg)
Total Funding:
$235.5M
Headquarters:
United States
Employee Number:
51-100
Estimated Revenue:
$10M to $50M
Last Funding Type:
Venture - Series Unknown
Technology:
Regenerative Medicine
Investor Type:
For Profit
Investors Number:
17
Founded Date:
1999-01-01
Industry:
Metabolism Dysfunctions